Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Gains from Sales and Divestitures (2022 - 2024)

BioRestorative Therapies (BRTX) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $97827.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Sales and Divestitures fell 5.97% year-over-year to $97827.0, compared with a TTM value of $97827.0 through Dec 2024, down 5.97%, and an annual FY2024 reading of $97827.0, down 5.97% over the prior year.
  • Gains from Sales and Divestitures was $97827.0 for Q4 2024 at BioRestorative Therapies, roughly flat from $97827.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $116486.0 in Q4 2022 and bottomed at $97827.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 3 years is $103009.7, with a median of $104043.0 recorded in 2023.
  • Peak annual rise in Gains from Sales and Divestitures hit 6.35% in 2023, while the deepest fall reached 10.68% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $116486.0 in 2022, then fell by 10.68% to $104043.0 in 2023, then dropped by 5.97% to $97827.0 in 2024.
  • Business Quant data shows Gains from Sales and Divestitures for BRTX at $97827.0 in Q4 2024, $97827.0 in Q3 2024, and $97827.0 in Q2 2024.